Trasylol Bayer AG stops sales of Trasylol.
Bayer AG to remove remaining supplies of its heart-surgery anti-bleeding drug Trasylol from the U.S. market.
The Food and Drug Administration said on Wednesday Bayer had notified the agency that it would begin removing remaining Trasylol stock from the U.S. market. Access will be limited to investigational use for certain patients who have no acceptable alternatives, the FDA said.
The FDA "supports Bayer's decision to completely remove Trasylol from regular use in the U.S. market," the agency said.
Dr. Wayne Ray and Dr. Michael Stein of Vanderbilt University in Tennessee commented by saying, ""Thus, in all likelihood, this is the end of the aprotinin story."
Bayer said it was removing Trasylol supplies from all countries where it remained in the supply chain, except where local authorities wanted to keep it in the market for special access programs.
The drugmaker "will work with health authorities to determine what impact, if any, the BART data and any other new data will have on the benefit-risk profile of Trasylol," Bayer spokeswoman Staci Gouveia via email
-----------------END------------------
60 Minutes does show on Bayer Drug Trasylol.
A renowned medical researcher estimates that 22,000 patients could have been saved if the Food and Drug Administration removed the heart surgery drug Trasylol two years ago.
In a scathing documentary the television show 60 Minutes tells of one researcher’s findings on the Bayer drug Trasylol.
Featured in the TV show is San Francisco medical researcher, Dr. Dennis Mangano who studied the drug use in 5,065 patients in 17 countries. His studies indicated that patients that were given Trasylol had a greater risk for renal (kidney) failure and other complications.
"It showed an important association between Trasylol use and kidney failure requiring dialysis, Mangano tells Pelley, “And it showed a trend toward increased death in hospital in these patients."
The story goes on to illustrate that Bayer had known the drug was unsafe and did not halt sales. The story also talks about the current role the FDA has in testing these drugs.
Trasylol FDA NEWS:
Bayer AG will stop all sales on its antibleeding drug Trasylol in the U.S. market due to expanding evidence that it may be linked to a higher risk of death than that of other drugs.
Trasylol was manufactured to help reduce or prevent blood loss during complicated procedures such as cardiac surgery. Excessive bleeding is a common and dangerous complication after major surgeries, and Trasylol reduces the likelihood of potentially life-threatening hemorrhaging. Blood loss is always dangerous, but after surgeries such as coronary artery bypasses it can be immediately fatal.
Unfortunately, according to a study of 4,374 coronary bypass artery patients published in the January 25 issue of the New England Journal of Medicine, Trasylol doubles the risk of renal failure and stroke and also increases the risk of heart failure or heart attack by 55%. Doctors continue to struggle with the complications of Trasylol, and are beginning to turn to generic drugs that provide the same benefits.
The Food and Drug Administration issued an advisory on February 9, 2006 to alert doctors to limit the use of Trasylol in patients during coronary artery bypass surgery due to the risk of potentially-fatal kidney trauma. There are a number of less expensive and dangerous generic drugs that could prevent renal failure in 9,000 to 11,000, but Bayer AG maintains that the findings of the FDA and the NEJM do not reflect the 15 years of data collected from their own studies.
If you or someone you love was injured by the severe side effects of Trasylol, you may be entitled to pursue financial compensation for your pain and suffering, but if you wait too long laws called statutes of limitations could prevent you from pressing your case. Let a dedicated and experienced defective drug attorney help you get you the restitution you deserve. Contact a Trasylol lawyer today.
In February of 2006, the Food and Drug Administration (FDA) issued a press release warning about Trasylol's unexpected side effects. Though the FDA did not specifically instruct physicians to stop using the medication during surgery, the strong language of the FDA release gave many pause. Was Trasylol worth the potentially devastating side effects? And was Trasylol approved before the drug went through enough clinical trials?
If you or someone you care about was given Trasylol and experienced any of the following side effects, you may be entitled to monetary compensation from Bayer (Trasylol's maker) for your suffering:
Trasylol Side Effects include the following:
- kidney problems
- heart attack
- stroke
- thrombosis
- myocardial infarction
- encephalopathy
Page Search Terms Include:
- Trasylol Lawsuit
- Trasylol Lawyer
- Trasylol Attorney
- Trasylol Injury
- Trasylol Claims
- Trasylol Kidney Problems
- Trasylol Heart Attack
- Trasylol Stroke
- Trasylol Myocardial Infarction
- Trasylol Class Action Lawsuits
Other Defective Drug Topics
- Accutane
- Actavis
- Actos
- ACE Inhibitors
- Ambien
- Anesthetic Creams
- Aranesp
- Aredia
- Avandia
- Bard Avaulta Mesh
- Bayer Diabetes Care Contour Test Strips
- Botox
- Byetta
- Carbamazepine
- Cefepime
- Celebrex
- Cialis
- Cipro
- Children's Cough and Cold Medication
- Colchicine
- Crestor
- Cytotec
- Depakote
- Dietary Supplements
- Digitek
- Dostinex
- Ephedra
- Epogen
- Femara
- Fen Phen
- Fentanyl Patches
- Fluorquinolone
- Fosamax
- Gadolinium
- Gardasil
- Heparin
- Januvia
- Ketek
- Kugel Mesh Patch
- Lamisil
- Leukine
- Levitra
- Meridia
- Mesothelioma Lawyer
- Metabolife
- Mifeprex
- Mirapex
- Mobic
- Multaq
- OB Tape
- Ortho Evra
- Paxil Lawsuit
- Phenergan
- Prempro
- Procrit
- Propecia
- Proton Pump Inhibitors
- Provigil
- Prozac
- Quinine
- Raptiva
- Reglan
